Granules India posts Q1 FY25 consolidated PAT higher at Rs. 134.64 Cr

Granules India has reported total income of Rs. 1181.92 crores during the period ended June 30, 2024

GSK’s RSV vaccine ‘Arexvy’ receives positive European Medicines Agency’s CHMP opinion for adults aged 50-59

Decision on EU marketing authorisation for this population expected by September 2024

Pfizer Ltd. posts Q1 FY25 PAT at Rs. 150.71 Cr

Pfizer Ltd. has reported total income of Rs. 604.70 crores during the period ended June 30, 2024

Aarti Drugs posts Q1 FY25 PAT lower at Rs. 33.3 Cr

Dr Reddys Laboratories posts Q1 FY25 consolidated PAT at Rs. 1,392 Cr

Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024

India reiterates commitment to adolescents on launch of ‘Economic Case for Investment in the Well-being of Adolescents in India’ report

Report highlights significant improvements in adolescent well-being in India

India established Comprehensive Lactation Management Centres for feeding low birth weight babies in ICUs

Access to breast milk for sick newborns admitted in intensive care units plays a lifesaving role

Steps taken by India for preparedness against future pandemics

Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting

USFDA completes inspection at Biocon Biologics’ facilities in Bengaluru

The inspection scope included 6 separate Biologics manufacturing units comprising 4 Drug Substance and 2 Drug Product manufacturing plants

Briefs: Indoco Remedies and Alembic Pharmaceuticals

Indoco Remedies is addressing the observations comprehensively and will respond to the USFDA within the stipulated timeframe